Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John M Bennett

Showing results (61-70 of 164) with videos related to

Pageof 17
Sort By:
Synlett : Accounts and Rapid Communications in Synthetic Organic Chemistry|August 9, 2021
Stereoselective Synthesis of (4<i>S</i>,5<i>S</i>)-5-Vinyloxazolidin-2-one-4-carboxylate as a β-Vinylserine Synthetic Equivalent by Vinyl Grignard Addition to an <i>N</i>-Tosyl Version of Garner's AldehydeErnest G Nolen, Yuqi M Cao, Brynn D Lewis, et al.
Leukemia Research|September 15, 2009
Phase I trials of amonafide as monotherapy and in combination with cytarabine in patients with poor-risk acute myeloid leukemiaSteven L Allen, Jonathan E Kolitz, Ante S Lundberg, et al.
Leukemia Research|May 18, 2007
Idiopathic cytopenia of undetermined significance (ICUS) versus low risk MDS: the diagnostic interfaceFriedrich Wimazal, Christa Fonatsch, Renate Thalhammer, et al.
Leukemia Research|September 17, 2011
Idiopathic cytopenia of undetermined significance (ICUS) and idiopathic dysplasia of uncertain significance (IDUS), and their distinction from low risk MDSPeter Valent, Barbara J Bain, John M Bennett, et al.
American Journal of Hematology|July 30, 2004
Donor cell myelodysplastic syndrome after allogeneic stem cell transplantation responding to donor lymphocyte infusion: case report and literature reviewRami Komrokji, Jainulabdeen J Ifthikharuddin, Raymond E Felgar, et al.
Leukemia & Lymphoma|October 21, 2003
A randomized trial of induction therapy (daunorubicin, vincristine, prednisone versus daunorubicin, vincristine, prednisone, cytarabine and 6-thioguanine) in adult acute lymphoblastic leukemia with long-term follow-up: an Eastern Cooperative Oncology Group Study (E3486)Peter H Wiernik, Peter A Cassileth, Traci Leong, et al.
Leukemia Research|March 22, 2017
New proposals of the WHO working group (2016) for the diagnosis of myelodysplastic syndromes (MDS): Characteristics of refined MDS typesCorinna Strupp, Kathrin Nachtkamp, Barbara Hildebrandt, et al.
Leukemia Research|March 24, 2004
A 2-year-old with atypical CML with a t(5;12)(q33;p13) treated successfully with imatinib mesylateBrenda Wittman, John Horan, Joanna Baxter, et al.
Journal of Visualized Experiments : Jove|January 25, 2018
Preparation of N-(2-alkoxyvinyl)sulfonamides from N-tosyl-1,2,3-triazoles and Subsequent Conversion to Substituted Phthalans and PhenethylaminesJohn M Bennett, Jonathan D Shapiro, Krystina N Choinski, et al.
Leukemia Research|April 12, 2003
Aggressive systemic mastocytosis and related mast cell disorders: current treatment options and proposed response criteriaPeter Valent, Cem Akin, Wolfgang R Sperr, et al.
Pageof 17

Showing results (61-70 of 164) with videos related to

Sort By:
Pageof 17
Synlett : Accounts and Rapid Communications in Synthetic Organic Chemistry|August 9, 2021
Stereoselective Synthesis of (4<i>S</i>,5<i>S</i>)-5-Vinyloxazolidin-2-one-4-carboxylate as a β-Vinylserine Synthetic Equivalent by Vinyl Grignard Addition to an <i>N</i>-Tosyl Version of Garner's AldehydeErnest G Nolen, Yuqi M Cao, Brynn D Lewis, et al.
Leukemia Research|September 15, 2009
Phase I trials of amonafide as monotherapy and in combination with cytarabine in patients with poor-risk acute myeloid leukemiaSteven L Allen, Jonathan E Kolitz, Ante S Lundberg, et al.
Leukemia Research|May 18, 2007
Idiopathic cytopenia of undetermined significance (ICUS) versus low risk MDS: the diagnostic interfaceFriedrich Wimazal, Christa Fonatsch, Renate Thalhammer, et al.
Leukemia Research|September 17, 2011
Idiopathic cytopenia of undetermined significance (ICUS) and idiopathic dysplasia of uncertain significance (IDUS), and their distinction from low risk MDSPeter Valent, Barbara J Bain, John M Bennett, et al.
American Journal of Hematology|July 30, 2004
Donor cell myelodysplastic syndrome after allogeneic stem cell transplantation responding to donor lymphocyte infusion: case report and literature reviewRami Komrokji, Jainulabdeen J Ifthikharuddin, Raymond E Felgar, et al.
Leukemia & Lymphoma|October 21, 2003
A randomized trial of induction therapy (daunorubicin, vincristine, prednisone versus daunorubicin, vincristine, prednisone, cytarabine and 6-thioguanine) in adult acute lymphoblastic leukemia with long-term follow-up: an Eastern Cooperative Oncology Group Study (E3486)Peter H Wiernik, Peter A Cassileth, Traci Leong, et al.
Leukemia Research|March 22, 2017
New proposals of the WHO working group (2016) for the diagnosis of myelodysplastic syndromes (MDS): Characteristics of refined MDS typesCorinna Strupp, Kathrin Nachtkamp, Barbara Hildebrandt, et al.
Leukemia Research|March 24, 2004
A 2-year-old with atypical CML with a t(5;12)(q33;p13) treated successfully with imatinib mesylateBrenda Wittman, John Horan, Joanna Baxter, et al.
Journal of Visualized Experiments : Jove|January 25, 2018
Preparation of N-(2-alkoxyvinyl)sulfonamides from N-tosyl-1,2,3-triazoles and Subsequent Conversion to Substituted Phthalans and PhenethylaminesJohn M Bennett, Jonathan D Shapiro, Krystina N Choinski, et al.
Leukemia Research|April 12, 2003
Aggressive systemic mastocytosis and related mast cell disorders: current treatment options and proposed response criteriaPeter Valent, Cem Akin, Wolfgang R Sperr, et al.
Pageof 17